SCHEMBL3133053

SCHEMBL3133053

COc1ccc(/C=C/C(=O)c2ccccc2)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.85
MEN1 O00255 1/20 0.85
KMT2A Q03164 1/20 0.85
NPC1 O15118 1/20 0.80
MAPT P10636 1/20 0.80
RAB9A P51151 1/20 0.80
TNFRSF1A P19438 2/20 0.76
NR1H4 Q96RI1 1/20 0.75
CYP1A1 P04798 2/20 0.74
CYP1A2 P05177 2/20 0.74
CYP2D6 P10635 2/20 0.74
CYP1B1 Q16678 2/20 0.74
CA1 P00915 1/20 0.74
CA2 P00918 1/20 0.74
CYP3A4 P08684 1/20 0.71
KDM4E B2RXH2 1/20 0.69
ALDH1A1 P00352 1/20 0.69
HPGD P15428 1/20 0.69
ALOX15 P16050 1/20 0.69
MAPK1 P28482 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30384064 1.00 ABCG2 (0.85) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL3133060 1.00 ABCG2 (0.85) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL10365559 1.00 ABCG2 (0.85) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL20106717 0.89 NR1H4 (0.76) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL13697612 0.89 TNFRSF1A (0.73) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL25203581 0.88 ABCG2 (0.86) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL25279622 0.88 TUBB1 (0.73) ABCG2MEN1KMT2ANPC1MAPT
SCHEMBL25240333 0.88 CXCL12 (0.82) MAPTCA1CA2KDM4E
SCHEMBL5598912 0.88 CXCL12 (0.82) MAPTCA1CA2KDM4E
SCHEMBL25211728 0.88 TUBB1 (0.73) ABCG2MEN1KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009927-A1 Anti-Inflammatory and Anti-Allergy Extracts from Nettle HERBALSCIENCE GROUP LLC (US) 2010-01-14 US claimed
WO-2026050367-A3 CHALCONE-RELATED HERBICIDES AND METHODS THEREOF COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2026-04-09 WO disclosed
WO-2026050367-A2 CHALCONE-RELATED HERBICIDES AND METHODS THEREOF COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2026-03-05 WO disclosed
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-20210154213-A1 PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES CALASIA PHARMACEUTICALS INC (US) 2021-05-27 US disclosed
EP-2307381-B1 NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2021-01-13 EP disclosed
EP-2687513-B1 DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2020-12-02 EP disclosed
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2019-10-08 US disclosed
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2019-10-08 US disclosed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-20060135445-A1 Breast cancer-resistant protein inhibitor KABUSHIKI KAISHA YAKULT HONSHA (JP) 2006-06-22 US disclosed
EP-1591112-A1 BREAST CANCER-RESISTANT PROTEIN INHIBITOR Kabushiki Kaisha Yakult Honsha (JP) 2005-11-02 EP disclosed
US-5492915-A ANTIINFLAMMATORY AGENTS RHONE-POULENC RORER S.A. (FR) 1996-02-20 US disclosed
US-5475132-A Fungicide intermediates RHONE-POULENC AGROCHIMIE (FR) 1995-12-12 US disclosed
US-5366982-A Antiinflammatory agents or antihistamines RHONE-POULENC RORER S.A. (FR) 1994-11-22 US disclosed
US-5342835-A Antifungal agents based on amides containing a phenyl group RHONE-POULENC AGROCHIMIE (FR) 1994-08-30 US disclosed
CN-1024317-C Antifungal agents based on amides containing phenyl group RHONE POULENC AGROCHIMIE (FR) 1994-04-27 CN disclosed
US-3959471-A 4,6-Diaryl-pyrimidin-2(1H)-ones as tranquilizers SANDOZ, INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135445-A1 Breast cancer-resistant protein inhibitor ABCC1, BCR, BRCA1 ABCG2 8/4885MEN1 4488/4885KMT2A 2476/4885
US-20210154213-A1 PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES CRYAA, CRYAB, TTR ABCG2 1316/4885MEN1 3695/4885KMT2A 4785/4885
US-11872236-B2 Pharmacological agents for treating ocular diseases CRYAA, CRYAB, TTR ABCG2 1316/4885MEN1 3695/4885KMT2A 4785/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 ABCG2 3643/4885MEN1 4505/4885KMT2A 4031/4885
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases PARK7, APP, HYPK ABCG2 1402/4885MEN1 1938/4885KMT2A 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.